Loading
GW
Guangzhou Wondfo Biotech Co.,Ltd Stock: price and insider trades · China
万孚生物
1 insider bought €1.2M of shares over the last 90 days, the latest filed 05 Aug 2026.
Guangzhou Wondfo Biotech Co.,Ltd: what insiders have been doing
This page follows insider dealings at Guangzhou Wondfo Biotech Co.,Ltd as filed with SSE / SZSE (CSRC), a company from the Health Care sector. Between 18 October 2025 and 18 October 2026, 2 insiders published 2 filings.
On the market, 1 insider bought (1 purchase totalling €1.2M) while 1 insider sold (1 sale totalling €75k). Taken together, the purchases exceed the sales by €1.1M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 board member. Biggest ticket of the year: €1.2M, bought by 王继华 and made public on 5 August 2026.
The last insider purchase was made public on 5 August 2026, 74 days ago.
Compared with its exchange (533 companies, median 2 filings), a count of 2 filings is typical. Our records for Guangzhou Wondfo Biotech Co.,Ltd go back to 2021, with 2 purchases and 5 sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Insider Decl.
7
Thresholds
n/a
Buy Volume
€1M
2 ops. · all time
Sell Volume
€86M
5 ops. · all time
Who traded when
BuySale彭仲雄1 sale
王继华1 buy
Since the insiders bought
- -2.9%Entry CN¥17.12 · Close at T+30 CN¥16.63
- -3.7%Entry CN¥34.48 · Close at T+365 CN¥33.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,703 of 24,158 companies
32.8
score / 100
Value28
Quality38
FCF yld2.1%
Earn yld-0.9%
EV/EBITDA44.4x
ROE-2.4%
Gross mgn57%
Net mgn-3.0%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥16.26
Analyst consensus
2 analysts1.25/5
CN¥20.36Target CN¥24.68(+52%)CN¥29.00
Income statement
RevenueCN¥2.1B
Gross profitCN¥1.2B57% margin
EBITDACN¥179.9M9% margin
Net income-CN¥63M-6.9% margin
Valuation
PER (forward)14.7x
P/Book1.4x
Beta0.83
Balance sheet & cash
Market capCN¥7.6B
Total debtCN¥601.7M
Free Cash FlowCN¥158.5M
Debt / Equity11%
Profitability & ownership
ROE-2.4%
ROA-1.7%
% insiders47.1%
% institutions3.2%
Last declaration on 5 August 2026
Declarations7 total
7 of 7 declarations
About Guangzhou Wondfo Biotech Co.,Ltd
万孚生物 is a company focused on the healthcare and pharmaceutical sector, specializing in the development of in vitro diagnostics. It is listed on the XSHE market.
